Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

Arthritis and Rheumatism

Volumn 39, Issue 2, 1996, Pages 257-265

  Drevlow, Barbara E ^a   Lovis, Rosa ^a   Haag, Mary Ann ^a   Sinacore, James M ^a   Jacobs, Cindy ^b   Blosche, Consuelo ^b   Landay, Alan ^c   Moreland, Larry W ^d   Pope, Richard M ^a,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b AMGEN INC   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CD14 ANTIGEN; CD3 ANTIGEN; CD69 ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 2 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MONOCYTE; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; DRUG ERUPTIONS; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL DISEASES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0030039524     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390212     Document Type: Article

References (36)

1. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW: Correlation of plasma Interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 2:706-709, 1988
2. Miyasaka N, Sato K, Goto M, Sasano M, Natsuyama M, Inoue K, Nishioka K: Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients: possible involvement in joint destruction. Arthritis Rheum 31:480-486, 1988
3. Koch AE, Kunkel SL, Chensue SW, Haines KG, Streiters RM: Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin Immunol Immunopathol 65:23-29, 1992
4. Arend WP, Dayer J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 38:151-160, 1995
5. Dinarello CA: The biology of interleukin-1. Chem Immunol 51:1-32, 1992
6. Dower SK, Sims JE, Cerretti DP, Bird TA: The interleukin-1 system: receptors, ligands and signal. Chem Immunol 51:33-64, 1992
7. Foxwell BMJ, Barrett K, Feldman M: Cytokine receptors: structure and signal transduction. Clin Exp Immunol 90:161-169, 1992
8. Slack J, McMahon CJ, Waugh S, Schooley K, Spriggs MK, Sims JE, Dower SK: Independent binding of interleukin-1 α and interleukin-1β to type I and type II interleukin-1 receptors. J Biol Chem 268:2513-2524, 1993
9. Symons JA, Eastgate JA, Duff GW: Purification and characterization of a novel soluble receptor for interleukin-1. J Exp Med 174:1251-1254, 1991
10. Gin JG, Newton RC, Horuk R: Identification of soluble interleukin-1 binding protein in cell free supernatants. J Biol Chem 265:17416-17419, 1990
11. Arend WP, Malyak M, Smith MF Jr, Whisenend TD, Slack JL, Sims JE, Giri JG, Dower SK: Binding of the IL-Iα, IL-1β, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors by synovial fluids. J Immunol 153:4766-4774, 1994
12. Dower Sk, Wignall JM, Schooley K, McMahan CJ, Jackson JL, Prickett KS, Lupton S, Cosman D, Sims JE: Retention of ligand binding activity by the extracellular domain of the IL-1 receptor. J Immunol 142:4314-4320, 1989
13. Femandez-Botran R: Soluble cytokine receptors: their role in immunoregulation. FASEB J 5:2567-2574, 1991
14. Fanslow WC, Sims JE, Sassenfeld H, Morrissey PJ, Gillis S, Dower SK, Widmer MB: Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 248:739-742, 1990
15. Jacobs CA, Baker PE, Roux ER, Picha KS, Toivola B, Waugh S, Kennedy MK: Experimental autoimmune encephalomyelitis is exacerbated by IL-1α and suppressed by soluble IL-1 receptor. J Immunol 146:2983-2989, 1991
16. Schorlemmer HU, Kanzy EJ, Langner KD, Kurrle R: Immunoregulation of SLE-like disease by the IL-1 receptor: disease modifying activity of BDF1 hybrid mice and MRL autoimmune mice. Agents Actions 39:c117-c120, 1993
17. Schorlemmer HU, Kanzy EJ, Langner KD, Kurrle R: Immunomodulatory activity of recombinant IL-1 receptor (IL-1-R) on models of experimental rheumatoid arthritis. Agents Actions 39:c113-c116, 1993
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Finals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988
19. Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA 140:659-662, 1949
20. Bray RA, Pope RM, Landay AL: Identification of a population of large granular lymphocytes obtained from the rheumatoid joint coexpressing the CD3 and CD16 antigens. Clin Immunol Immunopathol 58:409-418, 1991
21. Pope RM, Lovis RL, Gupta RS: Activation of synovial fluid T lymphocytes by 60-kd heat-shock proteins in patients with inflammatory synovitis. Arthritis Rheum 35:43-48, 1992
22. Verwilghen J, Corrigall V, Pope RM, Rodrigues R, Panayi GS: Expression and function of CD5 and CD28 in patients with rheumatoid arthritis. Immunology 80:96-102, 1993
23. Pope R, Drevlow B, Capezio J, Lovis R, Jacobs C, Blosch C, Beck C, Haag MA, Landay A: Intraarticular administration of recombinant human interleukin-1 receptor-type I in patients with active rheumatoid arthritis. In, Biologic Agents in Autoimmune Disease IV. (in press)
24. Malyak M, Swaney RE, Arend WP: Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies: potential contribution from synovial fluid neutrophils. Arthritis Rheum 36:781-789, 1993
25. Chin J, Rupp E, Cameron PM, MacNaul KL, Lotke PA, Tocci MJ, Schmidt JA, Bayne EK: Identification of a high affinity receptor for interleukin-1α and interleukin-1β on cultured rheumatoid synovial cells. J Clin Invest 82:420-426, 1988
26. Firestein GS, Berger AE, Tracey DE, Chosay JG, Chapman DL, Paine MM, Yu C, Zvaifler NJ: IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 149:1054-1062, 1992
27. Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, Arend WP: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 37:644-652, 1994
28. Svenson M, Hansen MB, Heegard P, Abell K, Bendtzen K: Specific binding of interleukin-1 (IL-1)β and IL-1 receptor antagonist (IL-1ra) to human serum: high affinity binding of IL-1rato soluble IL-1 receptor type I. Cytokine 5:427-435, 1993
29. Sternberg EM, Chrousos GP, Wilder RL, Gold PW: The stress response and the regulation of inflammatory disease. Ann Intern Med 117:854-866, 1992
30. Berton EW, Beach JE, Holiday JW, Smallridge RC, Fein HG: Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science 238:519-521, 1987
31. Sapolsky R, River C, Yamamoto G, Plotskly P, Vale W: Interleukin-1 stimulates the secretion of hypothalamic corticotropin releasing factor. Science 238:522-524, 1987
32. Besedovsky H, delRey A, Sorkin E, Dinarello CA: Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 233:652-665, 1986
33. Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F: Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 94:449-453, 1994
34. Mullarkey MF, Leiferman KM, Peters MS, Caro I, Roux ER, Hanna RK, Rubin AS, Jacobs C: Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol 152:2033-2041, 1994
35. Eugui EM, Almquist SJ: Antibodies against membrane interleukin Iα activate accessory cells to stimulate proliferation of T lymphocytes. Proc Natl Sci Acad USA 87:1305-1309, 1990
36. Re F, Muzio M, De Rossi M, Polentarutti, Giri JG, Mantovani A, Colotta F: The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 179:739-743, 1994